J Rheum Dis.  2025 Jan;32(1):1-2. 10.4078/jrd.2024.0133.

Optimization of biological therapy selection in rheumatoid arthritis: insights into anemia and interleukin-6 pathway

• Nam B

• KMID: 2562653
• DOI: http://doi.org/10.4078/jrd.2024.0133

Reference

1. Brown P, Pratt AG, Hyrich KL. 2024; Therapeutic advances in rheumatoid arthritis. BMJ. 384:e070856. DOI: 10.1136/bmj-2022-070856. PMID: 38233032.

2. Smolen JS, Landewé RBM, Bergstra SA, Kerschbaumer A, Sepriano A, Aletaha D, et al. 2023; EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis. 82:3–18. DOI: 10.1136/ard-2022-223356. PMID: 36357155.

3. Emery P, Gottenberg JE, Rubbert-Roth A, Sarzi-Puttini P, Choquette D, Taboada VM, et al. 2015; Rituximab versus an alternative TNF inhibitor in patients with rheumatoid arthritis who failed to respond to a single previous TNF inhibitor: SWITCH-RA, a global, observational, comparative effectiveness study. Ann Rheum Dis. 74:979–84. DOI: 10.1136/annrheumdis-2013-203993. PMID: 24442884. PMCID: PMC4431330.

4. Kim JG, Koo BS, Lee JH, Yoon BY. 2024; Anemia as an indicator of a higher retention rate for tocilizumab versus tumor necrosis factor inhibitors in patients with rheumatoid arthritis from a Korean multi-center registry. J Rheum Dis. 31:212–22. DOI: 10.4078/jrd.2024.0026. PMID: 39355549. PMCID: PMC11439637.

5. Anghel LA, Farcaş AM, Oprean RN. 2018; Medication adherence and persistence in patients with autoimmune rheumatic diseases: a narrative review. Patient Prefer Adherence. 12:1151–66. DOI: 10.2147/PPA.S165101. PMID: 30013327. PMCID: PMC6037147.

6. Kim J, Koh JH, Choi SJ, Jeon CH, Kwok SK, Kim SK, et al. 2021; KOBIO, the first web-based Korean biologics registry operated with a unified platform among distinct disease entities. J Rheum Dis. 28:176–82. DOI: 10.4078/jrd.2021.28.4.176. PMID: 37476366. PMCID: PMC10324910.

7. Raj DS. 2009; Role of interleukin-6 in the anemia of chronic disease. Semin Arthritis Rheum. 38:382–8. DOI: 10.1016/j.semarthrit.2008.01.006. PMID: 18336871.

8. Castell JV, Gómez-Lechón MJ, David M, Andus T, Geiger T, Trullenque R, et al. 1989; Interleukin-6 is the major regulator of acute phase protein synthesis in adult human hepatocytes. FEBS Lett. 242:237–9. DOI: 10.1016/0014-5793(89)80476-4. PMID: 2464504.

9. Ishibashi T, Kimura H, Shikama Y, Uchida T, Kariyone S, Hirano T, et al. 1989; Interleukin-6 is a potent thrombopoietic factor in vivo in mice. Blood. 74:1241–4. DOI: 10.1182/blood.V74.4.1241.1241. PMID: 2788464.

10. Nikolaisen C, Figenschau Y, Nossent JC. 2008; Anemia in early rheumatoid arthritis is associated with interleukin 6-mediated bone marrow suppression, but has no effect on disease course or mortality. J Rheumatol. 35:380–6.